References
- Mepolizumab (Nucala) for severe eosinophilic asthma. Med Lett Drugs Ther. 2016;58:11–12.
- U.S. Food and Drug Administration. December 12 2917 FDA News Release. FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588594.htm [last accessed 14 March 2018].
- Benralizumab (Fasenra) for severe eosinophilc asthma. Med Lett Drugs Ther 2018;60:33–34.
- Reslizumab (Cinqair) for severe eosinophilic asthma. Med Lett Drugs Ther 2016;58:81–82.
- Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon H-U, Schwartz LB, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215–1228.
- Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59:21–30.
- Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, O’Gorman MA, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:456–463.
- Suzuki Y, Suda T. Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: A review of the previous literature. Allergol Int 2018;67:334–340.
- Sano S, Yamagami K, Yoshioka K. Chronic eosinophilic pneumonia: a case report and review of the literature. Cases J 2009;2:7735.
- To M, Kono Y, Yamawaki S, Soeda S, Katsube O, Kishi H, To Y, et al. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract 2018;6:1746–1748.
- Salzman SH. The 6-min walk test: clinical and research role, technique, coding, and reimbursement. Chest 2009;135:1345–1352.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
- Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther 2015;53:1015–1027.
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
- Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017;376:1921–1932.
- Sergew A, Fernández Pérez ER. Current approach to diagnosis and management of pulmonary eosinophilic syndromes: eosinophilic pneumonias, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. Semin Respir Crit Care Med 2016;37:441–456.
- Allen J, Wert M. Eosinophilic pneumonias. J Allergy Clin Immunol Pract 2018;6:1455–1461.
- Kahn J-E, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Blétry O, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:267–270.
- Brown KK, King TE, Jr., Chronic eosinophilic pneumonia. In: Flaherty KR, ed. UpToDate. Waltham, MA: UpToDate Inc. Available from: http://www.uptodate.com [last accessed 13 Jul 2018].
- Valent P, Klion AD, Horny H-P, Roufosse F, Gotlib J, Weller PF, Hellmann A, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607–612.
- Ojanguren I, Chaboillez S, Lemiere C. Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma. J Allergy Clin Immunol Pract 2018; S2213–S2198.
- Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID, et al. Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma. J Allergy Clin Immunol Pract 2018;6:874–882.